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Abstract
Background:  Cdkn1c  encodes an embryonic cyclin-dependant kinase inhibitor that acts to
negatively regulate cell proliferation and, in some tissues, to actively direct differentiation. This
gene, which is an imprinted gene expressed only from the maternal allele, lies within a complex
region on mouse distal chromosome 7, called the IC2 domain, which contains several other
imprinted genes. Studies on mouse embryos suggest a key role for genomic imprinting in regulating
embryonic growth and this has led to the proposal that imprinting evolved as a consequence of the
mismatched contribution of parental resources in mammals.
Results: In this study, we characterised the phenotype of mice carrying different copy number
integrations of a bacterial artificial chromosome spanning Cdkn1c. Excess Cdkn1c  resulted in
embryonic growth retardation that was dosage-dependent and also responsive to the genetic
background. Two-fold expression of Cdkn1c in a subset of tissues caused a 10–30% reduction in
embryonic weight, embryonic lethality and was associated with a reduction in the expression of the
potent, non-imprinted embryonic growth factor, Igf1. Conversely, loss of expression of Cdkn1c
resulted in embryos that were 11% heavier with a two-fold increase in Igf1.
Conclusion: We have shown that embryonic growth in mice is exquisitely sensitive to the precise
dosage of Cdkn1c. Cdkn1c is a maternally expressed gene and our findings support the prediction
of the parental conflict hypothesis that that the paternal genome silences genes that have an
inhibitory role in embryonic growth. Within the IC2 imprinted domain, Cdkn1c encodes the major
regulator of embryonic growth and we propose that Cdkn1c was the focal point of the selective
pressure for imprinting of this domain.
Background
Genomic imprinting is an unusual epigenetic phenome-
non that results in the absence of expression of one copy
of an autosomal gene. This allele-specific expression is ini-
tiated by events that take place within the male and
female germ line during gametogenesis [1]. The parental
alleles acquire an epigenetic signature that is recognised in
the somatic cell and, as a result, there is permanent and
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heritable silencing of one parental allele. Studies on
imprinted genes in mice suggest a general role for imprint-
ing in the regulation of embryonic growth [2-8]. Two key
genes that regulate embryonic growth, insulin-like growth
factor 2 (Igf2) and insulin-like growth factor receptor 2
(M6P/Igf2r) are oppositely imprinted. In mice, insulin-
like growth factor 1 (Igf1) and the imprinted Igf2 are
thought to be the two major growth signalling molecules.
These factors work in combination with at least three
receptors, the insulin receptor (Insr), insulin-like growth
factor receptor 1 (Igf1r) and the imprinted Igf2r to exert
local and systemic effects on growth [3].
Single genetic or epigenetic changes can deregulate the
function of an imprinted gene and they are particularly
vulnerable targets for numerous human pathologies
(recently reviewed in [9-11]. Since the cost of adopting
monoallellic gene expression to an individual is clearly
quite high, there must be a compelling reason for mam-
mals to imprint their genes. The most widely accepted
model that has been proposed to explain the evolution of
genomic imprinting is known as the parental conflict
hypothesis [12,13]. This hypothesis focuses on the asym-
metry in mammals between parental contributions to the
developing fetus. Although larger offspring are thought to
be of benefit to both parents, in females there must be a
balance between the fitness of the offspring and survival
of the mother. Genomic imprinting of the paternal
genome may have evolved to promote growth of the fetus
while imprinting of the female genome occurred to coun-
teract the effects of the paternal genome in order for the
mother to survive and produce more offspring. However,
deficiency in expression of an imprinted gene does not
always lead to an embryonic growth phenotype [14].
Careful studies have revealed effects on mammalian
behaviour for several genes [6,7,15-19] which suggests
that the role of genomic imprinting may be more complex
or that some genes are imprinted by virtue of their prox-
imity to imprinting centres (ICs).
While studies on loss of function are important for our
understanding of gene function by itself, over expression
studies may provide more unequivocal information on
the significance of imprinting of a particular gene. Bial-
lelic gene expression can be studied in mice with unipa-
rental disomy [20-22] or in mice where a targeted deletion
of an imprinting centre (IC) has released genes from
imprinting [23-25]. These studies generally involve multi-
ple genes and, in regions where there are both paternally
and maternally expressed genes, can also involve loss of
expression. The primary advantage of using large genomic
clones to analyse imprinted genes is that the exact nature
and number of genes is defined by the transgenic
sequence, there is no loss of expression and the genes are
expressed from their endogenous promoters at the appro-
priate level and time, predominantly without being
affected by the site of integration [26].
Cdkn1c, also known as p57Kip2, encodes a maternally
expressed, cyclin-dependant kinase inhibitor (CDKi) [27-
30]. Expression is tissue-specific and at high levels in cells
entering mitotic arrest [27,28]. Loss of expression of
Cdkn1c through maternal inheritance of a targeted dele-
tion results in severe developmental abnormalities
[31,32], similar to that seen in humans with loss of
CDKN1C in Beckwith-Wiedemann syndrome (BWS) [33-
37]. As with all CDKis, excess Cdkn1c induces cell cycle
arrest [27,28]. Forced expression of Cdkn1c in retinal cul-
tures leads to premature cell cycle exit [38] and Cdkn1c co-
expression with Nurr1  promotes maturation of a mid-
brain dopaminergic neuronal cell line [39] demonstrating
a role for Cdkn1c in both cell cycle regulation and cellular
differentiation.
The  Cdkn1c  gene is located within a large cluster of
imprinted genes on mouse distal chromosome 7 [29].
Maternal disomy of this region results in embryonic and
extra embryonic growth retardation and embryonic
lethality [22]. There are two ICs within this domain con-
trolling two mechanistically distinct sub domains
[25,40,41]. Imprinting of Cdkn1c is achieved through IC2,
also known as KvDMR1 [25] and mice paternally inherit-
ing a targeted deletion of the KvDMR1 locus show growth
retardation. Growth retardation is also associated with
maternal transmission of an 800 kb YAC transgene span-
ning eleven genes from Nap1l4 to Th but excluding the
IC1 domain [42]. All these studies involve multiple
imprinted genes and dissecting which gene is responsible
for a particular phenotype is not straightforward. None-
theless, the proportionality of the growth retardation in
all these mice suggests a systemic effect on growth. Since
Igf2, which encodes a potent embryonic mitogen, is unaf-
fected by the KvDMR1 deletion, one or more of the other
deregulated genes may play a novel role in regulating
whole organism growth.
In this study, we characterised the phenotype of mice car-
rying different copy number integrations of a bacterial
artificial chromosome spanning Cdkn1c. We show copy-
number dependent embryonic growth retardation that is
most severe on the 129/Sv genetic background. By using a
modified BAC transgene spanning the same genomic
region but with an inactivated Cdkn1c, we can assign the
embryonic phenotype to Cdkn1c alone. These data indi-
cate that Cdkn1c encodes the most important regulator of
embryonic growth within the IC2 domain on mouse dis-
tal chromosome 7.BMC Developmental Biology 2007, 7:53 http://www.biomedcentral.com/1471-213X/7/53
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Results
Excess Cdkn1c causes embryonic lethality
Following on from our previous work on studying the
mechanism of imprinting of Cdkn1c [43,44], we investi-
gated the consequences of over expressing Cdkn1c in vivo
on development. We generated transgenic mice carrying
an 85 kb bacterial artificial chromosome (BAC) spanning
the Cdkn1c locus [44] (Figure 1A). When ES cell lines with
low copy number insertions of this transgene (1–4) were
aggregated with MF1 morulae, there was a high incidence
of perinatal loss (Table 1). No live born chimeras were
obtained for high copy lines (Table 1). When surviving
chimeras from four independent lines were crossed to out
bred MF1 females, transgenic offspring were detected at
the expected frequency (Table 2). When these same chi-
meras were crossed with 129/Sv females, transgenics were
recovered at low frequency in a single copy line (1/33)
and not at all in three other lines containing 2–4 copies of
the transgene (Table 2). We examined litters at earlier time
points and dying transgenic embryos were observed at
varying stages, some as early as E10.5 (Line 5B6, four cop-
ies).
We have previously shown that the transgenic Cdkn1c
transcript is expressed only in a subset of tissues from this
85 kb BAC at E13.5 by in situ hybridisation [44]. Immu-
nohistochemistry with a Cdkn1c-specific antibody
showed a similarly restricted distribution of the Cdkn1c
protein at E12.5, mainly to neural tissues (Figure 1B). Real
Time RT-PCR measurements of the Cdkn1c transcript
revealed an increase in the overall expression of 1.36-fold
in whole embryos carrying a single copy of the BAC trans-
gene (line 5D3) and 1.75-fold in embryos carrying two
copies (line 5A4) at E13.5 (Figure 1C). This reflects the
restricted expression from the BAC which we confirmed in
E12.5 embryos by comparing the levels of expression in
the head versus the body in the single copy line (Figure
1D). This is consistent with expression from the single-
copy transgene at levels similar to the endogenous gene in
neural tissues where we know the transgenic Cdkn1c to be
expressed. We were not able to detect over expression of
Cdkn1c in the body. We know from our in situ data,
immunohistochemistry and a reporter transgene [44] that
Cdkn1c is expression from the BAC in only a subset of the
non-neuronal tissues where endogenous Cdkn1c is
expressed such as the lung endothelium and the develop-
ing kidney tubules. The endogenous Cdkn1c is expressed
most strongly in skeletal muscle and cartilage, where we
do not see expression from our transgene. This very strong
expression maybe masking the more subtle changes in tis-
sues where there is a relatively lower level expression of
Cdkn1c. These data are consistent with copy-number
dependent expression of Cdkn1c from the BAC in a subset
of tissues.
Growth is exquisitely sensitive to the dosage of Cdkn1c
The transgenic offspring from the cross between the chi-
meric males and the MF1 females were noticeably smaller
than their wild type littermates. The degree of growth
retardation increased with increasing copy number of the
transgene and persisted after weaning (Figure 2A). Persist-
ent growth retardation was also observed when the single
copy transgene was bred onto the C57/BL6 background
for three generation (Fig 2B).
The degree of growth retardation also varied with strain
background. Transgenic F1 males (50%:50%; 129/
Sv:MF1) from a single copy line, 5D3, were 11.3% smaller
at three weeks but when these males were crossed with
129/Sv females, the transgenic F2 male offspring
(75%:25%; 129/Sv:MF1) were 29% smaller than their
non-transgenic litter mates (Figure 2C, two tail student t-
Test: P = 0.017). Generation 3 C57B/L6 males showed an
intermediate phenotype of 20% growth retardation at this
time point (Figure 2C, P = 0.02). In contrast the lethality
associated with an increasing contribution of the 129/Sv
genetic background, no evidence of lethality was associ-
ated with the presence of a single copy of the transgene on
the C57BL/6 background (data not shown).
We examined the age at which males acquired sexual
maturity as judged by the timing of their first mating.
Despite their small size, transgenic male adult mice
reached sexual maturity at the same time as wild type lit-
termates and were fertile (Table 3). The majority of
females also reached sexual maturity at a similar age to
their wild type littermates but there was one female that
had a litter late and two that did not have litters during the
time of observation (Table 3). Those that had litters were
able to nest and feed their offspring. It should be noted
that there is variable fertility in the rare surviving females
that are deficient in Cdkn1c  [45]. The Cdkn1c-deficient
mice also show a severe postnatal growth defect. This is
consistent with a defect in pituitary development. It is
possible that, given the expression of Cdkn1c from our
transgene in the pituitary, further studies on transgenics
animals with a higher 129/Sv genetic contribution might
reveal an endocrine defect in adults and this is under
investigation.
Cdkn1c is a cell cycle inhibitor that acts intrinsically to
limit cell proliferation. We would expect that the tissues in
which there was excess Cdkn1c would be disproportion-
ately smaller than those without. We examined the
weights of organs with no excess Cdkn1c (heart, spleen,
testes and liver) and those in which there had been excess
embryonic Cdkn1c (kidney and brain, Figure 2D) in eight-
week old males. There were no significant difference in
comparison to body weight (P = 0.12–0.87) between wild
type and transgenic males. Growth retardation induced byBMC Developmental Biology 2007, 7:53 http://www.biomedcentral.com/1471-213X/7/53
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the presence of a single copy BAC was not restricted to the
tissues in which the transgenic Cdkn1c was expressed.
The transgenic embryos were small but similar in appear-
ance to wild type embryos (Figure 3A) in all four lines. At
E13.5, transgenic embryos from line 5D3 (single copy) on
a mixed MF1:129/Sv background are 14% smaller than
wild type (Figure 3B; P = 7.2 × 10-7). This phenotype is
comparable to that reported for the KvDMR1 deletion and
the 800 kb YAC where several additional genes are also
Physical map of the telomeric end of the imprinted domain in mouse distal chromosome 7 in relation to the position of the  BAC transgene and expression analysis of transgenic lines Figure 1
Physical map of the telomeric end of the imprinted domain in mouse distal chromosome 7 in relation to the 
position of the BAC transgene and expression analysis of transgenic lines. A) Top line shows a genomic map of the 
IC2 region on distal mouse chromosome 7. Hatched region marks the KvDMR1 region that is methylated only on the maternal 
allele. The black arrowhead marks the position of the IC2 control region for the domain. Arrows indicate direction of tran-
scription. Below is the map of the 85 kb Cdkn1c transgene (BAC144D14). Filled boxes show the positions of the intact genes. 
In addition to Phlda2, Slc22a18 and Cdkn1c, the transgene includes the 3' UTR of Napl14 (white box) but not the 5' UTR. The 
modified BAC used to generate line 10–15 has a β-galactosidase-neomycin (β-geo) fusion gene inserted into Cdkn1c indicated by 
the white arrowhead and black filled box. B) Localisation of the Cdkn1c protein expressed from the BAC transgene. Sagittal 
section of E12.5 wild type and Cdkn1c-null/BAC transgene (KO/Tg) embryos stained with a Cdkn1c-specific antibody. Endog-
enous Cdkn1c is most strongly expressed in skeletal and cardiac muscle, cartilage and the developing pituitary with lower 
expression in neuronal tissues. The transgenic expression is predominantly only neural, indicated by the black arrows, and in a 
subset of cells in the pituitary, kidney, lung and adrenal gland. C) Quantitative RT-PCR data for Cdkn1c at E13.5 for 5D3 (single 
copy line) and 5A4 (two copy line) transgenic embryos and 10–15 (Cdkn1c-βgeo) at E12.5. Cdkn1c levels were normalised 
against three reference genes: Gapdh, Actin and 18S RNA. Cdkn1c was at 1.36-fold wild type levels in the single copy line and 
1.75-fold endogenous in the two copy line. Cdkn1c levels were not significantly raised in the control line, 10–15 (Cdkn1c-βgeo). 
D) Quantitative RT-PCR data for Cdkn1c at E12.5 for 5D3 (single copy line) showing the difference in expression between 
head, where the transgene is predominantly expressed, and the body, where the transgene is only expressed in a small subset 
of tissues. This is consistent with copy number dependent expression of Cdkn1c from the transgene in a subset of tissues.
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over expressed [25,42]. In contrast, embryos null for
Cdkn1c were 11% heavier wild type embryos at E13.5 (Fig-
ure 3D, P = 0.008).
Phenotype is due to excess Cdkn1c
The transgene spans two other genes, Phlda2 (also known
as Ipl or Tssc3) [46] and Slc22a18 (also known as Impt1 or
Tssc5) [47]. The growth retardation and embryonic
lethality could be a consequence of over expression of any
one of these genes. To test this possibility, we examined
the transgenic line, 10–15 (Cdkn1c-βgeo). This line con-
tains three copies of the same BAC but the Cdkn1c gene on
the BAC has been inactivated by the insertion of a reporter
gene (Figure 1A) [44]. In these mice, Cdkn1c is not over
expressed in the embryo (Figure 1C). Phlda2  and
Slc22a18, which are predominantly expressed in extra
embryonic tissues [45,47], are highly over expressed in
Table 2: Embryonic lethality in transgenic animals on pure a 129/Sv background.
Line (copy number) MF1 female (Transgenic/Total number) 129/Sv female (Transgenic/Total number)
5D3/129 (1) 13/23 1/35*
Generation 3 5D3 n.t. 1/33**
5A4/129 (2) 3/9 0/16
5A2/129 (2) 2/5 0/10
5B6/129 (4) 6/10 0/20
10–15/129 (3) N.d. 48/109***
The transgene was present at the expected frequency (50% of the adult offspring, P = 0.5) when chimeras were mated with MF1 females but there 
was a significant reduction in survival of transgenics for single copy line 5D3 (number of transgenic animals/total number genotyped = 1/35, *P = 
0.0001) and no survivors for the other lines when chimaeras were crossed with inbred 129/Sv females. F1 males from line 5D3 (50%:50%; MF1 × 
129/Sv) were backcrossed onto 129/Sv for three generations (G3). At which point significant lethality was again noted (1/33 transgenics from eight 
litters, **P = 0.06). The modified transgene (10–15) bred six generations into the 129/Sv background showed no significant difference in survival 
(***P = 0.20).
Table 1: Contribution of transgenic ES cells to coat colour and germ line transmission in chimeras.
Line Copy no. Chimeras/total number born % 129/Sv Coat colour % Transmission 129/Sv coat colour
5D3 1 11/11 (5 d.e. pups died) 100 100
100 100
100 100
100 100
100 100
100 100
5C2 1 10/10 (9 d.e died) 80 12.5
6C1 1 2/2 (one d.e. died) 100 100
5A4 2 6/6 100 100
100 100
100 100
100 100
30 100
0 n.t.
5A2 2 7/8 (4 d.e. died) 100 100
100 100
100 N.t.
30 n.t
5B6 4 4/9 (2 d.e died) 60 100%
40 (female) n.t.
5A6 4–8 0/8 - -
6A3 4–8 0/9 - -
5A3 4–8 0/5 - -
6A4 4–8 0/0 - -
129/Sv ES were aggregated with MF1 morula to generate chimaeric animals containing both ES cells (agouti) and the host MF1 cells (albino). The 
contribution of ES to the adult chimera was estimated by the percentage of agouti in the coat colour and found to decrease with increasing copy 
number. Additionally, 50% (21/40) of the pups with dark eyes (d.e.), indicating a strong contribution of ES cells, were born dead or die shortly after 
birth.
n.t. = not tested.BMC Developmental Biology 2007, 7:53 http://www.biomedcentral.com/1471-213X/7/53
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the placenta [48] but not detectable in the embryo at
E13.5 (data not shown).
No embryonic lethality was observed when we first gener-
ated this line or when we backcrossed the mice for six gen-
erations onto the 129/Sv background (Table 2). This
contrasts with almost complete loss of transgenic animals
(1/34 transgenic/wild type) after crossing 5D3 F1 males
(50:50; 129/Sv × MF1) onto the 129/Sv background for
three generations (>93% 129/Sv). There was no signifi-
cant difference in weights between males from line 10–15
(Cdkn1c-βgeo) and wild type littermates at three weeks
(Figure 2B, P  = 0.24) and embryos from line 10–15
(Cdkn1c-βgeo) are not significantly different to their wild
Postnatal growth retardation in mice carrying Cdkn1c transgene Figure 2
Postnatal growth retardation in mice carrying Cdkn1c transgene. A) Post natal growth curves of males from one to 
eight weeks for lines 5D3 (one copy, n = 2), 5A4 (two copy, n = 3) and 5B6 (four copies, n = 2) and their wild type littermates 
(n = 9). Mice carrying the transgene are significantly smaller in all lines (Statistical significance using Student's t-test P < 0.017 for 
all lines). All weights were obtained from F1 mice born from a cross between a chimaeric male founder (129/Sv) and a MF1 
female. B) Post natal weight data from one to ten weeks of males for the single copy line, 5D3, bred onto the C57/BL6 back-
ground for three generation showing persistence of growth retardation after weaning (one copy, Tg n = 9, WT n = 8). C) 
Weights at 3 weeks of male mice from line 5D3 (one copy, Tg n = 4, WT n = 9) on a 50%:50%; 129/Sv × MF1 background 
labelled as 5D3/MF1) compared with a 75%:25% background labelled as 5D3/129 (Tg n = 6, WT n = 8). Interaction with a 
genetic factor within the 129/Sv background results in a more severe growth retardation, increasing from 11.3% to 28.8% (Sta-
tistically significant change using Student's t-test. P = 0.014). On a C57BL/6 background, the growth retardation is intermediate 
at 20.5% (Tg n = 9, WT n = 8). No significant growth retardation is observed in transgenic line 10–15 on a 129/Sv background 
(Tg n = 8, WT n = 4, P = 0.24). This line carries three copies of the modified BAC where transgenic Cdkn1c is not functional 
demonstrating that growth retardation is likely due to excess Cdkn1c. C) Comparison of organ weights in wild type and 5D3 
transgenic adult males at 8–10 weeks. Growth retardation is not restricted to organs in which there was excess embryonic 
Cdkn1c WT n = 9 and Tg n = 6). *denotes tissues that were exposed to excess Cdkn1c during embryogenesis.
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type counter parts (P = 0.24) at E13.5 (Figure 3C). This
line was generated by pronuclear injection and it was pos-
sible that we selected against any transgenic lines showing
an adverse phenotype. Therefore, we also examined
embryos at E13.5 after a second round of pronuclear
injection. Seven embryos representing independent inte-
gration events were identified. No significant difference in
embryonic size was noted (data not shown).
Placental insufficiency can also cause embryonic growth
retardation in mice as illustrated by the placental specific
Igf2 knock out [49]. Both the unmodified and modified
BAC transgenic lines have a placental defect due to excess
Phlda2 and/or Slc22a18 ([48] and our unpublished data).
In the absence of over expression of Cdkn1c in line 10–15
(Cdkn1c-βgeo), this placental defect leads to a slow down
in embryonic growth detectable at E16.5 [48]. In the lines
with excess Cdkn1c, we observe embryonic growth retar-
dation three days earlier, at E13.5. Our control line 10–15
(Cdkn1c-βgeo) embryos are of normal weight at E13.5
(Figure 3C). Therefore, this earlier defect in embryonic
growth is due to excess Cdkn1c and not due to the placen-
tal insufficiency shared by both lines. Furthermore, a key
characteristic of IUGR due to placental insufficiency in
mice is postnatal "catch up" growth [49]. Our mice do not
recover their growth potential after birth (Figure 2A). Even
at one year, they are noticeably smaller than their wild
type siblings (data not shown).
We can conclude that excess Cdkn1c in the embryo causes
sustained growth retardation and, on the 129/Sv genetic
background, also causes embryonic lethality.
Igf1 expression is reduced as a consequence of increased 
Cdkn1c levels
Cdkn1c acts intrinsically to regulate cell proliferation and,
in some tissues, also directs differentiation. However,
growth retardation was not limited to the tissues in which
there was an embryonic excess Cdkn1c. One possible
explanation was that excess Cdkn1c altered the expression
level of one of the key embryonic growth regulatory genes
which would then have an extrinsic effect on growth. We
used quantitative Real Time RT-PCR to measure the tran-
script levels of several genes known to regulate embryonic
growth. At E11.5 we identified a reduction in Igf1 in our
two-copy line but not in our single-copy line. Igf1 was
reduced in both the single-copy and the two-copy trans-
genic lines at E13.5 when there was obvious growth retar-
dation (Figure 4A). Igf2 levels were slightly raised at E11.5
in both lines and reduced at E13.5 only in the two-copy
line (Figure 4B).
In the single copy line, we only detected changes in Igf1 at
E13.5, when the growth retardation phenotype was well
established. In order to detect more subtle changes in gene
expression at an earlier time point in this line, we exam-
ined Igf1 and Igf2 levels in RNA prepared separately from
the head and in the body of E12.5 embryos. Cdkn1c
expression from our transgene was predominantly in neu-
ral tissues and we reasoned that we would be more likely
to detect a change in expression in material where this tis-
sue predominates. When we examined the transgenic
embryos, we found that the level of Igf1 in the head was
dramatically reduced to 40% of the wild type level (Figure
4C). In the body, where we have minimal over expression
of Cdkn1c, Igf1 levels were not significantly changed from
normal. The central nervous system is a major site for
expression of Igf1 [50,51]. Consistent with this observa-
tion, we found that, in wild type embryos, there was 9.5-
fold more Igf1 RNA in the head than in the body at E12.5
(data not shown). Igf2 levels were raised in the head by
two-fold and reduced in the body by 50%. Since the body
(mesodermal tissues) is the primary source of Igf2 [2], the
overall change in expression in the transgenic embryos
was not significant.
Table 3: Excess Cdkn1c does not affect sexual maturity.
Age at 1st plug (days) Age at 1st litter (days)
WT males 5D3 male WT female 5D3 female
43 39 54 58
38 37 56 69
39 38 58 57
37 38 56 55
46 56 56
37 55 57
Average (s.d.) 40 (3.69) 38 (0.82) 56 (1.33) 59 (5.16)
There was no significance difference in time to first plug between transgenic males and wild type littermates (P = 0.33). Transgenic females had their 
litters slightly later than wild type females. Although this difference did not show up as significant (P = 0.22), there was a large variation in timing 
within the transgenic females from 56 to 69 days. Furthermore, two females in this study never became pregnant.BMC Developmental Biology 2007, 7:53 http://www.biomedcentral.com/1471-213X/7/53
Page 8 of 14
(page number not for citation purposes)
To provide further data to support a role for Igf1 in the
growth phenotype, we examined Igf1 and Igf2 levels in
RNA prepared from the heads and bodies of embryos null
for Cdkn1c at E12.5. We again found changes in the level
of expression of Igf1  with a three-fold increase in Igf1
expression levels in the head and difference in expression
in the body (Figure 4C). Igf2  levels were relatively
unchanged in both samples (Figure 4D).
We have found an inverse correlation between the level of
expression of Cdkn1c and the level of expression of the
potent growth factor Igf1. These data are consistent with a
role for this growth factor in our growth phenotype. Igf1
levels are linked, either directly or indirectly, to level of
expression of Cdkn1c  and growth is either retarded or
enhanced as a consequence.
We have shown that Cdkn1c acts as a true rheostat for
embryonic growth, with loss of expression after gene dele-
tion leading to overgrowth and over expression of Cdkn1c
causing growth retardation.
Embryonic growth is exquisitely sensitive to Cdkn1c levels Figure 3
Embryonic growth is exquisitely sensitive to Cdkn1c levels. A) Image of a wild type and a transgenic embryo from line 
5A4 (two copies) at E16.5 shows demonstrable growth retardation. The embryos appear normally proportioned. B) A com-
parison of wild type and transgenic embryo weights at E13.5 for line 5D3 (single copy unmodified BAC, Tg n = 22, WT n = 21). 
These embryos are from 129/Sv females mated with transgenic males maintained on an MF1 background. Transgenic embryos 
weigh significantly less than wild type embryos (86%, P = 7.2 × 10-7). C) A comparison of wild type and transgenic weight at 
E13.5 of embryos for line 10–15 (three copy BAC with an inactive transgenic Cdkn1c locus and no excess Cdkn1c, Tg n = 30, 
WT n = 22). The line was maintained on a 129/Sv background. Transgenic embryos are not significantly different in weight to 
wild type embryos (104%, P = 0.24). D) A comparison of wild type and transgenic weights at E13.5 of embryos inheriting a tar-
geted Cdkn1c allele maternally (null for Cdkn1c, Tg n = 19, WT n = 16). The line was maintained on a 129/Sv background. 
Transgenic embryos weigh significantly more than wild type embryos (111%, P = 0.008).
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Discussion
Embryonic growth is exquisitely sensitive to the dosage of 
Cdkn1c
Excess expression of Cdkn1c from a single copy BAC trans-
gene resulted in decreased growth of embryos from at
least E13.5 with no catch-up growth after birth. Further-
more, as the level of excess Cdkn1c increased, the size of
the animals decreased. Initial reports for the phenotype of
Cdkn1c null mice did not reveal a clear affect on growth at
birth [31,32]. However, we found that loss of Cdkn1c was
associated with embryonic overgrowth earlier in develop-
ment, at E13.5. Therefore, Cdkn1c acts as a true rheostat
for embryonic growth.
Cdkn1c is the most important regulator of embryonic 
growth within the IC2 domain
Studies on mono-parental embryos and embryos with
paternal or maternal disomy of specific chromosomal
regions revealed a key role for imprinted genes in regulat-
ing embryonic growth. These studies invariably involved
both loss of expression and excess expression of multiple
genes and the identification of the target for imprinting of
the locus is difficult. Embryos with maternal disomy of
mouse distal chromosome 7 showed embryonic and extra
embryonic growth retardation and embryonic lethality
[22] with loss of expression of Igf2 and Ins2 and excess
expression of a number of genes presumed to include
Quantitative analysis of growth factor expression levels in response to excess embryonic Cdkn1c Figure 4
Quantitative analysis of growth factor expression levels in response to excess embryonic Cdkn1c. A) Quantitative 
RT-PCR data for Igf1 on whole embryos from lines 5D3 and 5A4. At E11.5, there is a slight reduction in Igf1 in the two-copy 
line. At E13.5, there is a reduction in Igf1 levels in both lines. B) Quantitative RT-PCR data for Igf2 on whole embryos from 
lines 5D3 and 5A4. At E11.5, there is a slight increase in Igf2 in both lines while at E13.5, there is a significant decrease in Igf2 in 
the two-copy line. C) Comparison of expression of Igf1 at E12.5 in the single copy line, 5D3, head compared with body and 
whole Cdkn1c null embryos. In line 5D3, Igf1 levels are 60% less than wild type levels in the head where transgenic Cdkn1c is 
predominantly expressed but relatively unaffected in the body. In null embryos, Igf1 levels are raised by three-fold in the head. 
D) Comparison of expression of Igf2 at E12.5. In line 5D3, Igf2 levels are raised by two-fold in the head but 50% wild type lev-
els in the body. In null embryos, Igf2 levels are similar to wild type.
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Cdkn1c, Ascl2 and Phlda2 (summarised in Figure 5). Pater-
nal inheritance of a targeted deletion of the KvDMR1,
which resulted in loss of imprinting of only the IC2
domain, resulted in a slightly less severe growth retarda-
tion [25] similar to maternal inheritance of the 800 kb
YAC spanning all the genes within this domain [42]. Our
unmodified BAC, which spans only three of these genes,
also caused embryonic growth retardation. The modified
BAC, which drives excess Phlda2 and Slc22a18 but not
excess Cdkn1c, did not. Therefore, Cdkn1c is the only gene
in this region that has been shown to have a major role in
regulating embryonic growth.
Embryonic lethality in embryos with maternal disomy of 
the distal 7 domain may be due to excess Cdkn1c
There are differences in survival between embryos with
maternal disomy of distal chromosome 7 and those with
paternal inheritance of the KvDMR1 deletion. This could
be interpreted to indicate that the embryonic lethality in
the mice with maternal disomy of distal 7 was due to loss
of Igf2 and/or Ins2. However, embryonic lethality was not
been reported for loss of Igf2  [2] or Ins2  [52] alone.
Although lethality could be due to a combination of loss
of Igf2 with excess Cdkn1c, we have observed embryonic
lethality associated with excess Cdkn1c and normal Igf2
levels on the 129/Sv genetic background.
Altered expression of Igf1 in response to changes in the 
dosage of Cdkn1c
Our data showed that increasing expression levels of
Cdkn1c were associated with a decrease in the size of the
embryo, starting prior to E13.5. As the level of Cdkn1c
increased, we found a consistent decrease in the transcript
level of the potent embryonic growth factor, Igf1, which
was detectable as early as E11.5 in our two-copy line. Con-
versely, loss of expression of Cdkn1c was associated with a
reciprocal phenotype with the null embryos being 11%
heavier than wild type embryos at E13.5 with a three-fold
increase in Igf1 at E12.5. Complete loss of Igf1 results in
embryonic growth retardation from E13.5 [53,54]. Simi-
lar to our 5D3 mice, Igf1  heterozygotes are 10–20%
smaller at birth and remain this small as adults [54].
Cdkn1c is the key regulator of embryonic growth within the IC2 imprinted domain on mouse distal chromosome 7 Figure 5
Cdkn1c is the key regulator of embryonic growth within the IC2 imprinted domain on mouse distal chromo-
some 7. Summary of the reported genotypes and phenotypes associated with the imprinted genes on mouse distal chromo-
some 7. Black arrowheads indicate the positions of the known IC for the two domains. The number of expressed gene copies 
present in each genotype is shown with the top row being the normal, wild type state. The reported weight phenotypes are for 
maternal disomy distal chromosome 7 [22], paternal inheritance of the KvDMR1 deletion [25], maternal inheritance of an 800 
kb YAC [42] and data from this paper. The strain backgrounds are C57BL/6 where indicated.
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Although no significance size difference was reported at
E13.5 in the Igf1  heterozygotes, genetic modifiers may
provide an explanation for this discrepancy since our pre-
liminary data suggest a weaker growth retardation pheno-
type in the C57BL/6 background on which the Igf1 studies
have all been performed.
We also observed disturbances in the level of expression
of a second key growth factor transcript, Igf2. However,
this was only in the Cdkn1c overexpressing mice and not
in the Cdkn1c null mice. Also, we have some limited data
from genetic crosses with mice over expressing Igf2 [55]
that do not support a major role for this growth factor in
our phenotype. It is therefore probable that reduced
expression of Igf1 was responsible for growth retardation
in the presence of excess Cdkn1c. This would also provide
an explanation for why growth retardation was not
restricted to the tissues in which there was excess Cdkn1c
since Igf1 acts extrinsically to regulate growth. It will be
possible to test this in genetic crosses when mice over
expressing Igf1  from an endogenous promoter become
available.
There are a number of ways in which the cell cycle inhib-
itor,  Cdkn1c, could act on Igf1. Although we cannot
exclude a direct role for Cdkn1c in regulating the expres-
sion of the Igf1 gene, it seems more plausible that the cell
cycle inhibitor acts indirectly, for example by reducing the
proliferative potential of the cells in which Igf1  is
expressed or by altering the differentiation program of a
particular cell type expressing the growth factor.
While it has been known for some time that imprinting
acts directly to regulate embryonic growth via the epige-
netic modification of key genes, our data suggests that
imprinting can also act indirectly to regulate the levels of
non-imprinted embryonic growth factors. This further
highlights the complexity and the importance of genomic
imprinting in mammalian growth and development.
Imprinting of Cdkn1c comes at a high cost
Loss of expression of this gene is perinatal lethal in mice
and linked to BWS in humans [33-37]. We have shown
that excess Cdkn1c can be equally detrimental to develop-
ment in mice and there is some evidence for this in
humans [56]. Given the increased frequency of intrauter-
ine growth retardation in babies conceived after assisted
reproductive technologies conceptions [57-59] and a
prevalence of imprinting mutations in these children [60-
63], excess CDKN1C may be an important factor in IUGR
in humans which should be explored further.
Imprinting of Cdkn1c may have played a role in the 
transition towards increased maternal investment in 
embryonic growth in placental mammals
The parental conflict hypothesis predicts that over expres-
sion of a gene expressed only from the maternal genome
should limit embryonic growth. We have presented the
first compelling evidence that overexpression of Cdkn1c
alone causes growth retardation and therefore the paren-
tal conflict hypothesis holds true for this gene. Our work
may also provide further clues to the evolutionary conse-
quence of imprinting this important gene. Imprinting has
for some time been thought to have emerged prior to the
divergence of marsupials from eutherians [64-66]. How-
ever, unlike Igf2, Cdkn1c is not imprinted in marsupials
[67]. Therefore, the IC1 domain, containing the potent
growth factor gene, Igf2, acquired an imprint prior to the
divergence of marsupials and eutherians and the IC2
domain, containing Cdkn1c, became imprinted after this
divergence. It may be significant that one key difference
between marsupials and eutherians is the size and matu-
rity of the offspring at birth and this correlates with the
role that we have identified for Cdkn1c  in regulating
embryonic growth.
Conclusion
By using different copy number transgenes and mice car-
rying a targeted deletion of Cdkn1c, we have shown that
embryonic growth is exquisitely sensitive to the dosage of
Cdkn1c. Since Cdkn1c  encodes the major regulator of
embryonic growth within the IC2 imprinted domain, we
propose that Cdkn1c was the focal point of the selective
pressure for imprinting of this domain. Cdkn1c is a mater-
nally expressed gene and our findings support the predic-
tion of the parental conflict hypothesis that that the
paternal genome will silence genes that have an inhibitory
role in embryonic growth. Furthermore, since Cdkn1c
acquired its imprinted status after marsupials diverged
from placental mammals, our data would support a role
for the change in dosage of Cdkn1c gene in the relative
increase size of the embryo in eutherians.
Methods
Mice
All animal studies and breeding was approved by the Uni-
versities of Cambridge and Cardiff ethical committees and
performed under a UK Home Office project licenses.
Inbred 129/Sv and C57BL/6 and out bred MF1 mice were
maintained at the Gurdon Institute, Cambridge, UK and
Cardiff School of Biosciences. Additional 129/Sv mice
were purchased from B+K Universal. Transgenic lines car-
rying the 85 kb bacterial artificial chromosome were
described previously [44,68]. Essentially, ES cell lines
were made by co-electroporation of the linearised BAC
with a linearised pgk-neomycin construct and selecting for
neomycin positive colonies. Genomic DNA from theseBMC Developmental Biology 2007, 7:53 http://www.biomedcentral.com/1471-213X/7/53
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colonies was analysed by Southern blotting. Intactness
and copy number of the BAC integrations was determined
by probing the membrane first with the complete 85 kb
BAC (after blocking repeats with total mouse genomic
DNA) and then with a single copy probe to Neuronatin
[69]. Lines carrying 1–8 copies of the BAC were co-cul-
tured with MF1 morulae to generate chimaeric animals.
The lines were maintained on a mixed 129/Sv × MF1 back-
ground. F1 5D3 (50%:50%; 129/Sv × MF1) denotes ani-
mals that have an equal contribution of MF1 and 129/Sv
from a cross between a male chimera and a MF1 female,
F2 5D3 (75%:25%; 129/Sv × MF1) denotes animals that
have a greater contribution of 129/Sv obtained by cross-
ing a F1 5D3 (50%:50%; 129/Sv × MF1) male with a 129/
Sv female. Animals were genotyped by PCR using primers
that identified the pBeloBAC vector sequence (R85: 5'-
attctgcttacacacgatgc-3' and R86: 5'-ttccgcagaggtcaatcc-3').
Generation of line 10–15, which contains the modified
BAC transgene with an inactivated Cdkn1c gene (Cdkn1c-
βgeo), was previously described [44]. These mice were
maintained on a 129/Sv background as were mice carry-
ing a targeted allele of Cdkn1c [31]. All mice were tailed
between P7 and P14 and genomic DNA for genotyping
was prepared as described [70].
Sexual maturity was determined by daily checking for
plugs and the appearance of a litter.
Weighing studies
Postnatal weights of males were taken at weekly intervals
for one to eight weeks. At 8–10 weeks, males were killed
by cervical dislocation. Organs were dissected and kept
frozen on dry ice before weights were obtained. Embry-
onic weights were taken 11, 12 or 13 days after a discern-
able plug, at E11.5, 12.5 or 13.5. Embryos were stored in
RNAlater (Sigma) while genotyping data was obtained
from yolk sac DNA.
Statistics
Statistical significance (Probability values) was deter-
mined using the Student's t-Test (two tailed distribution
and two sample unequal variance). The significance in the
difference in observed over the expected appearance of a
particular genotype was determined using the Chi-
squared Test.
Quantitative RNA analysis
Total RNA was prepared from embryos using TRI Reagent
(Sigma). cDNA was prepared using M-MuLV reverse tran-
scriptase (Roche) with random hexamers under the man-
ufacturers conditions. 20 μl cDNA was diluted five-fold in
10 mM Tris.HCl (pH 7.5) and stored at -20°C. For the
quantitative PCR, primers were designed to amplify across
introns for all the genes using the Primer3 program [71]
unless otherwise stated. Quantitative RT-PCR was per-
formed in duplicate on two independent samples and on
two separate occasions on diluted RT+ and RT- material
prepared for wild type and transgenic embryos using
DyNAmo HS SYBR Green qPCR kit (Finnzymes), GRI 96
PCR detection plates and ABsolute QPCR seal (ABgene)
and detected using the Chromo 4 Four-Color Real Time
detector (MJ Research). Conditions for amplification: 15
minutes at 95°C (to release polymerase) followed by 40
cycles of 30 seconds at 95°C and 1 minute at 63°C
(anneal and extension). 1 μl of diluted cDNA was ampli-
fied in a total sample volume of 25 μl with 25 pmoles of
each primer. Primers were 5'-agagaactgcgcaggagaac-3' and
5'-tctggccgttagcctctaaa-3' for Cdkn1c, 5'-ggcattgtggatgagt-
gttg-3' and 5'-tctcctttgcagcttcgttt-3' for Igf1, 5'-gtcgatgttggt-
gcttctca-3' and 5'-aagcagcactcttccacgat-3' for Igf2 and 5'-
cgctgagccagtcagtgtag-3' for 18S.  Gapdh  and  Beta-actin
primers were as previously described [72,73].
Immunohistochemistry
E12.5 embryos were fixed in pre-cooled Carnoys (60%
ethanol, 30% chloroform, and 10% glacial acetic acid) for
25 min at 4°C, then washed three times for 2 min in 96%
ethanol, then 100% ethanol for 2 and 7 min, respectively.
Embryos were then cleared in 1:1 ethanol/chloroform (V/
V) for 10 min and chloroform for 10 min, then 1hr.
Embryos were then impregnated in three changes of 56–
58°C melting point paraffin wax (Sigma-Aldrich) for 30
min each at 65°C and embedded. 10 μm sections were
dewaxed in xylene and rehydrated through a series of
graded ethanol. Washes in PBS with 0.02% Tween 20 were
carried out between each subsequent step. Endogenous
peroxidases were quenched by incubation in 3% hydro-
gen peroxide in water for 5 min, then 0.5% hydrogen per-
oxide in methanol for 1 hr. Sections were blocked in 2.5%
horse blocking serum (RTU VECTASTAIN universal quick
kit, Vector Labs) for 1 hr. Goat anti-CDKN1C primary
antibody M-20 (SC-1039, Santa Cruz) was diluted 1/50 in
0.04% horse blocking serum and incubated at 4°C over-
night. Primary antibody was removed and secondary anti-
body and streptavidin/peroxidase steps were carried out
as per manufacturers instructions (RTU VECTASTAIN uni-
versal quick kit, Vector Labs). Sigma Fast DAB substrate
system was used to visualise staining. Sections were coun-
terstained with Gills III hematoxylin for 1 min then
destained for 1 min with acid/alcohol solution (0.5%
HCl, 70% ethanol). Sections were dehydrated through a
series of graded ethanol and washed in xylene before
mounting with DPX mounting medium.
Abbreviations
BAC Bacterial Artificial Chromosome
BWS Beckwith-Weidemann Syndrome
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IC Imprinting Centre
PCR Polymerase Chain Reaction
RT Reverse transcriptase
YAC Yeast Artificial Chromosome
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